Tags

Type your tag names separated by a space and hit enter

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
Blood. 2020 05 21; 135(21):1912-1915.Blood

Links

Publisher Full Text
ncbi.nlm.nih.gov
ashpublications.org
PMC Free PDF

Authors+Show Affiliations

Treon SP
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
Castillo JJ
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
Skarbnik AP
Lymphoproliferative Disorders Program, Novant Health, Charlotte, NC; and.
Soumerai JD
Department of Medicine, Harvard Medical School, Boston, MA. Massachusetts General Hospital, Boston, MA.
Ghobrial IM
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
Guerrera ML
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.
Meid K
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA.
Yang G
Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, MA. Department of Medicine, Harvard Medical School, Boston, MA.

MeSH

Agammaglobulinaemia Tyrosine KinaseAgedBetacoronavirusCoronavirus InfectionsFemaleHumansLung InjuryMaleMiddle AgedPandemicsPneumonia, ViralProtein Kinase InhibitorsPyrazolesPyrimidinesWaldenstrom Macroglobulinemia

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32302379

Citation

Treon, Steven P., et al. "The BTK Inhibitor Ibrutinib May Protect Against Pulmonary Injury in COVID-19-infected Patients." Blood, vol. 135, no. 21, 2020, pp. 1912-1915.
Treon SP, Castillo JJ, Skarbnik AP, et al. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020;135(21):1912-1915.
Treon, S. P., Castillo, J. J., Skarbnik, A. P., Soumerai, J. D., Ghobrial, I. M., Guerrera, M. L., Meid, K., & Yang, G. (2020). The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood, 135(21), 1912-1915. https://doi.org/10.1182/blood.2020006288
Treon SP, et al. The BTK Inhibitor Ibrutinib May Protect Against Pulmonary Injury in COVID-19-infected Patients. Blood. 2020 05 21;135(21):1912-1915. PubMed PMID: 32302379.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. AU - Treon,Steven P, AU - Castillo,Jorge J, AU - Skarbnik,Alan P, AU - Soumerai,Jacob D, AU - Ghobrial,Irene M, AU - Guerrera,Maria Luisa, AU - Meid,Kirsten, AU - Yang,Guang, PY - 2020/4/18/pubmed PY - 2020/6/2/medline PY - 2020/4/18/entrez SP - 1912 EP - 1915 JF - Blood JO - Blood VL - 135 IS - 21 SN - 1528-0020 UR - https://www.unboundmedicine.com/medline/citation/32302379/full_citation L2 - https://ashpublications.org/blood/article-lookup/doi/10.1182/blood.2020006288 DB - PRIME DP - Unbound Medicine ER -